Business Update | 21-Nov-2024 | 07:00 | RNS |
Q3 Trading Update | 29-Oct-2024 | 07:00 | RNS |
Results from Phase 3 paediatric study | 25-Sep-2024 | 07:00 | RNS |
Interim results | 04-Sep-2024 | 07:00 | RNS |
ACCRUFeR® Approved by Health Canada | 27-Aug-2024 | 07:00 | RNS |
Notice of interim results | 14-Aug-2024 | 07:00 | RNS |
Unaudited Q2 2024 Trading Update | 24-Jul-2024 | 07:01 | RNS |
Directorate Change | 24-Jul-2024 | 07:00 | RNS |
$5.7m Milestone Monetization Agreement with AOP | 03-Jul-2024 | 07:00 | RNS |
Results of 2024 Annual General Meeting | 20-Jun-2024 | 16:25 | RNS |
New Drug Application for Accrufer® in South... | 28-May-2024 | 07:00 | RNS |
Audited results for the year ended 31 Dec 2023 | 10-May-2024 | 15:30 | RNS |
Business Update for Q1 2024 | 30-Apr-2024 | 07:00 | RNS |
Notice of Results | 16-Apr-2024 | 07:00 | RNS |
Unaudited Full Year Trading Update | 21-Feb-2024 | 07:00 | RNS |
Currency | UK Pounds |
Share Price | 2.95p |
Change Today | 0.28p |
% Change | 10.28 % |
52 Week High | 7.65p |
52 Week Low | 1.23p |
Volume | 40,674,235 |
Shares Issued | 782.06m |
Market Cap | £23.07m |
Beta | 1.88 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 0 |
Buy | 0 |
Neutral | 1 |
Sell | 0 |
Strong Sell | 0 |
Total | 1 |
No dividends found |
Time | Volume / Share Price |
16:30 | 50,000 @ 2.95p |
16:25 | 500,000 @ 3.23p |
16:24 | 250,000 @ 2.90p |
16:17 | 33,878 @ 2.94p |
16:16 | 15,000 @ 2.94p |
You are here: research